磁刺激
荟萃分析
医学
随机对照试验
评定量表
萧条(经济学)
帕金森病
内科学
置信区间
严格标准化平均差
心理干预
心理学
物理疗法
疾病
深部经颅磁刺激
精神科
刺激
发展心理学
经济
宏观经济学
作者
Jianing Chen,Peikun He,Yuhu Zhang,Yuyuan Gao,Yihui Qiu,You Li,Qingxi Zhang,Limin Wang,Zhiheng Huang,Jiehao Zhao,Kun Nie,Lijuan Wang
标识
DOI:10.1080/00207454.2020.1744591
摘要
Background: Nowadays, antidepressants still are the mainstay of treatment for depression in Parkinson’s disease (PD) but some recent studies report that medication might aggravate motor symptoms in PD patients. This meta-analysis aims to assess the effect of non-pharmacological treatments for depression in patients with PD.Materials and Methods: Only randomized controlled trials (RCTs) were included. The participants were PD patients with comorbid depression (dPD). The interventions had the equivalent effect of non-pharmacological treatments alone compared with control(s). Scores of depression scale were selected as the primary outcome, while scores of Unified Parkinson’s Disease Rating Scale part III and the incidence of side effects were the secondary outcome. The statistics were pooled and presented as weighted mean differences (WMDs), standardized mean differences (SMDs), or risk ratios (RRs) with their 95% confidence intervals (CIs).Results: Fifteen articles were eventually included; twelve studies reported on repetitive transcranial magnetic stimulation (rTMS) and three used cognitive behavioral therapy (CBT). Other interventions failed to have qualified studies. Our data indicated that both rTMS and CBT could significantly improve depression scores in a short term (SMD = −0.621, 95% CI [−0.964, −0.278]; SMD = −1.148, 95% CI [−1.498, −0.798], respectively). In addition, rTMS could alleviate motor symptom (WMD = −2.617, 95% CI [−4.183, −1.051]) and was relatively safe (RR = 1.054, 95% CI [0.698, 1.592]).Conclusion: Our data suggest that rTMS can safely alleviate depression and motor symptoms in dPD at least for a short period. Moreover, compared with clinical monitoring, CBT can improve depressive symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI